Sign up to save your podcasts
Or
Share BillionToOne Closes $15M Series A+ Funding
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BillionToOne Closes $15M Series A+ Funding
BillionToOne Closes $15M Series A+ Funding Back to HomeMENLO PARK, CA, BillionToOne has closed its follow-on Series A+ funding round of $15 million.
BillionToOne, Inc., the precision diagnostics company that invented the patent-pending QCT molecular counter platform, announced today that it has closed its follow-on Series A+ funding round of $15 million with select global investors.
Previous investors, Hummingbird Ventures and NeoTribe Ventures led the investment round with participation from Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul, and HOF Capital.
This brings the total funding that BillionToOne has raised to more than $32.5 million.
Current non-invasive prenatal tests (NIPTs) exclude single-gene inherited disorders like cystic fibrosis and spinal muscular atrophy because they can only detect large chromosomal abnormalities greater than one million base-pairs. | To read full story, visit https://startuparound.com/read/1583951406.3302083/BillionToOne-Closes-$15M-Series-A+-Funding?ref=audio_experience
View all episodes
By Startup AroundBillionToOne Closes $15M Series A+ Funding Back to HomeMENLO PARK, CA, BillionToOne has closed its follow-on Series A+ funding round of $15 million.
BillionToOne, Inc., the precision diagnostics company that invented the patent-pending QCT molecular counter platform, announced today that it has closed its follow-on Series A+ funding round of $15 million with select global investors.
Previous investors, Hummingbird Ventures and NeoTribe Ventures led the investment round with participation from Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul, and HOF Capital.
This brings the total funding that BillionToOne has raised to more than $32.5 million.
Current non-invasive prenatal tests (NIPTs) exclude single-gene inherited disorders like cystic fibrosis and spinal muscular atrophy because they can only detect large chromosomal abnormalities greater than one million base-pairs. | To read full story, visit https://startuparound.com/read/1583951406.3302083/BillionToOne-Closes-$15M-Series-A+-Funding?ref=audio_experience